New Rochelle, NY, September 10, 2013—Use of stimulant medications to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents has increased significantly over the past several years. This trend toward increased use of prescription stimulants extends beyond ADHD to other types of neuropsychiatric disorders in children and teens as well, including Autism Spectrum Disorder (ASD), according to a study published in Journal of Child and Adolescent Psychopharmacology (JCAP), a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available on the JCAP website.
Søren Dalsgaard, MD, PhD, Helena Skyt Nielsen, PhD, and Marianne Simonsen, PhD, Aarhus University (Denmark), Lundbeck Foundation Initiative for Integrative Psychiatric Research (Denmark), and Hospital of Telemark (Norway), conducted a study of more than 850,000 children born in Denmark between 1990 and 2001. They found that 61% of children with ADHD, 16% of children with ASD, and 3% of those with other psychiatric disorders were treated with one or more medications typically prescribed for ADHD—methylphenidate, dexamphetamine, and atomoxetine. The data indicated significant increases in the prescription rates of these medications during the years 2003 to 2010.
“This study utilizes a population-based national cohort of children and adolescents, and assesses stimulant treatment in children and adolescents with ASD,” says Harold S. Koplewicz, MD, Editor-in-Chief of JCAP, and President, Child Mind Institute, New York, NY. “This is the largest and first prospective study to quantify the change in the use of treatment with ADHD medications over time.”
About the Journal
Journal of Child and Adolescent Psychopharmacology (JCAP) is an authoritative peer-reviewed journal published 10 times a year online with Open Access options and in print. The Journal is dedicated to child and adolescent psychiatry and behavioral pediatrics, covering clinical and biological aspects of child and adolescent psychopharmacology and developmental neurobiology. Complete tables of content and a sample issue may be viewed on the JCAP website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Cyberpsychology, Behavior, and Social Networking and Games for Health Journal. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s over 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.
Contact: Vicki Cohn, (914) 740-2156, email@example.com
New Rochelle, NY, February 19, 2013–A large study of nearly half a million older adults followed for about 12 years revealed a clear trend: as coffee drinking increased, the risk of death decreased. Study author Neal Freedman, PhD, MPH, National Cancer Institute, discusses the significance of these findings and the potential links between coffee drinking, caffeine consumption, and various specific causes of disease in an interview in Journal of Caffeine Research, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available on the Journal of Caffeine Research website.
“Epidemiology of Caffeine Consumption and Association of Coffee Drinking with Total and Cause-specific Mortality” presents an in-depth interview exploring the many factors that could contribute to the association between coffee, disease, and mortality.
Dr. Freedman examines the relationship between coffee drinking and behaviors such as smoking and alcohol abuse, the physiological effects of caffeine on blood pressure and cardiac function, and the importance of differentiating between the effects of coffee and caffeine.
“Given the near-universal daily consumption of caffeine, Dr. Freedman‘s research underscores the urgent need for randomized controlled trials to identify which components of coffee and other caffeine beverages benefit or harm consumers, under what circumstances, and in relation to which health outcomes,” says Jack E. James, PhD, Editor-in-Chief of Journal of Caffeine Research.
About the Journal Journal of Caffeine Research: The International Multidisciplinary Journal of Caffeine Science is a quarterly journal published in print and online that covers the effects of caffeine on a wide range of diseases and conditions, including mood disorders, neurological disorders, cognitive performance, cardiovascular disease, and sports performance. The Journal explores all aspects of caffeine science including the biochemistry of caffeine; its actions on the human body; benefits, dangers, and contraindications; and caffeine addiction and withdrawal, across all stages of the human life span from prenatal exposure to end-of-life. Complete tables of content and a sample issue may be viewed on the Journal of Caffeine Research website.
About the Publisher Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Breastfeeding Medicine, Journal of Medicinal Food, and Journal of Child and Adolescent Psychopharmacology. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 70 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.